Certain factors may increase the likelihood of experiencing bloating on GLP-1 therapy, including: Pre-existing gastrointestinal conditions such as irritable bowel syndrome (IBS), functional dyspepsia, or small intestinal bacterial overgrowth (SIBO) Rapid dose escalation without adequate titration periods Dietary factors , particularly high intake of fermentable carbohydrates (FODMAPs), fatty foods, or carbonated beverages Concurrent medications that affect gastrointestinal motility Patients should be aware that GLP-1 receptor agonists have been associated with more serious gastrointestinal adverse effects, including pancreatitis (inflammation of the pancreas) and gallbladder disease
Monitoring: Regular follow-up appointments ensure progress is on track and any side effects or adjustments can be addressed promptly
This hypothesis is speculative, but challenging
The medication works identically to Ozempic: it activates GLP-1 receptors in the brain to suppress appetite, slow digestion, and stabilize blood sugar
At standard doses, they are used to treat obesity and type 2 diabetes
GLP-1 medications delay gastric emptying through multiple mechanisms
